InsomniaCBT-pINCT07636408
Post-Concussion Sleep and Brain-heart Functions
A study testing CBT-pI and Sleep Hygiene in people with Insomnia and Concussion Post Syndrome, run by University of Ottawa.
Trial summary
This project is designed as a randomized controlled trial (RCT), with an active control group. Sleep and heart rate will be monitored at home for 1 week before and after the intervention. Questionnaires will be completed from home before, during and 8 weeks after the end of the Intervention. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Insomnia, Concussion Post Syndrome
- What is being tested?
- CBT-pI and Sleep Hygiene
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- Jun 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults 18 years and older
- Experiencing persisting post-concussion symptoms > 4 weeks but no more than 12 months post-injury as measured based on home-made screening questions and the Sport Concussion Assessment Tool (SCAT6)
- Having a Sleep Condition Indicator score suggestive of insomnia (SCI =/< 15, adapted to enable the inclusion of insomnia symptoms over at least 1 month)
- Meeting diagnostic criteria for insomnia disorder on the SCID
- Having a smartphone, tablet or computer and willingness to install a sleep intervention application on it
Who cannot join
- Having undergone another CBT-I program within the past 6 months
- Current diagnosis of bipolar disorder, psychotic disorder, or substance use disorder confirmed by the M.I.N.I.
- Self-reported substance use disorder (i.e., alcohol, cannabis, or illicit drugs) or =/> monthly use of illicit drugs reported on item-2 of the WHO-ASSIST (except tobacco, alcohol, and cannabis)
- Body mass index > 45
- Shift work or rotating shifts within 1 month of study entry
- Recent travel to a different time zone (leaving 1 week of recovery per time zone difference)
Show all 10Show fewer
- Any clinically significant neurological disorder aside from concussion (including seizure disorder)
- Signs of sleep apnea as reflected by combined profiles on the Sleep Disorders Symptoms Checklist-25 and Epworth Sleepiness Scale
- Unstable psychotropic medications (need to be on a stable dose for at least 1 month prior to study start)
- Insufficient English skills to provide informed consent, understand study instructions, or fill out questionnaires
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Enhancing Sleep to Improve Brain-heart Functions in People With Persistent Post-concussion Symptoms
This project is designed as a randomized controlled trial (RCT), with an active control group. Sleep and heart rate will be monitored at home for 1 week before and after the intervention. Questionnaires will be completed from home before, during and 8 weeks after the end of the Intervention. The Cognitive Behavioural Therapy for Insomnia, adapted for post-concussed individuals (CBT-pI) and control interventions, will be delivered on a digital online platform over an 8-week period. Participants in the control arm will be offered CBT-pI after the follow-up period. All intervention arms will be delivered as adjuncts to standard clinical care. All other treatments received during the intervention will be documented.
Read the detailed description
- Background and Rationale Up to 50% of individuals who sustain a concussion experience sleep disturbances. Poor sleep has been found predictive of poorer outcomes in post-concussion recovery. In Canada, insomnia constitutes a major burden upon public health. Insomnia not only impairs sleep quality but also exacerbates cognitive, emotional, and physiological post-concussion symptoms, including cardiovascular dysfunctions, such as elevated heart rate and sympathetic overactivation; thus, possibly leading to delayed recovery following a concussion. Furthermore, recent work in chronic insomnia identified increased levels of brain microstructure injury biomarkers previously linked to concussion. These disruptions can potentially interfere with brain-heart functions and delay post-concussion recovery. As such, treating insomnia may result in better post-concussion recovery, which may notably be observable through biomarkers linked to brain-heart health. Cognitive-Behavioural Therapy treatment for insomnia (CBT-I) is the first line of treatment recommended for chronic primary insomnia sufferers. It combines multipronged strategies involving education and progressive personalized sleep manipulations to address the maladaptive cognitive and behavioural processes contributing to the maintenance of insomnia. Five distinct intervention components - stimulus control, time in bed restriction therapy, psychoeducation about sleep, cognitive therapy, and relaxation training - are included within the CBT-I framework. CBT-I has been found effective to address sleep issues emerging after a concussion, with documented benefits for post-concussion recovery. This may notably operate via the restoration of brain-heart functions since CBT-I enhances brain functions following concussions, may influence autonomic regulation by reducing hyperarousal and sympathetic overactivation, and improves cardiovascular outcomes. One of the putative mechanisms of action of CBT-I resides in increased deep sleep due to enhanced sleep pressure. Deep sleep is a state characterized by high amplitude low frequency brain activity in the delta frequency range on the electroencephalogram (EEG). Recent discoveries highlight the role of deep sleep in autonomic regulation and healing processes. Post-concussion sleep has been associated with increased deep sleep. One may postulate that higher increases in delta activity driven by CBT-I may be associated with enhanced autonomic functions and post-concussion symptoms recovery. The investigators recently expanded previous results suggesting that individuals with insomnia have low coherence between brain and heart activity. To the best of our knowledge, research has yet to investigate whether successful insomnia treatment, through CBT-I, restores brain-heart interactions, and how changes in brain, heart, and brain-heart interactions may relate to post-concussion symptoms recovery following CBT-I.
- Study Objectives Primary objective:
- Evaluate the efficacy of a digital CBT-I program adapted for post-concussion syndrome (CBT-pI) on insomnia symptoms (primary outcome) and biomarkers related to post-concussion brain-heart function (secondary outcomes) Secondary objectives:
- Evaluate treatment acceptability and satisfaction
- Collate feedback about potential adaptations to better address challenges linked to insomnia treatment in the context of post-concussion brain-heart function
- Explore putative brain-heart mechanisms associated with CBT-pI responses based on EEG markers, heart rate and heart rate variability, sleep-based EEG-ECG interactions, and cognitive performance
- Methods
3.1. Contact Pathway Participants will be recruited through the 360 Concussion Care (360CC) clinic. The participants will be referred by clinicians at this clinic to members of the research team. Clinicians will identify patients they would like to refer to the study, request that these patients fill out the "Permission to be contacted form", and send this form to the research team. A research assistant will then contact the potential participant through email to send them a summary of the study and a link to complete an anonymous online screening form for the first set of eligibility criteria on a secured web platform (Qualtrics, www.qualtrics.com; license held via the University of Ottawa) and a unique identification code. The first question of this online form will ask participants to confirm their consent to take part in the screening process. This will be documented in the screening database. The second question of this online screening form will ask participants to insert their unique anonymous research screening code. This screening form will notably include items assessing neurologic and psychiatric history and medications, and will include the Sleep Condition Indicator (SCI), WHO-ASSIST item 2, Sleep Disorders Symptoms Checklist-25 (SDS-CL-25), and Epworth Sleepiness Scale. It should take between 10 and 15 minutes to complete.
3.2. Ongoing Consent Procedure For participants found to be eligible after the screening, the research assistant will call participants to summarize the next steps of the study verbally and address any questions or concerns that participants may have. At which point, verbal consent will be obtained to conduct a structured interview using the Mini International Neuropsychiatric Interview (M.I.N.I) and the insomnia module of the SCID to determine the last set of eligibility criteria.
After this interview, eligible participants will be sent an electronic form containing the information and consent form (ICF) and will have as much time as the participant needs to read it at home before enrolling in the study. As part of that same electronic form, the participant will confirm consent by ticking consent boxes and entering their full name. This information will be stored in a consent database showing the participant's full name and consent date, which will be kept on restricted-access folders on the ROMHC's server in separate files than the research data. This online consent form was created based on published guidelines from peer-reviewed articles. Special care will be given to ensure that participants understand that their participation is entirely voluntary and that the participant can withdraw from the study at any stage (without any consequence on the treatment[s] they receive at the 360CC clinic or their relationship with any of the clinicians at the 360CC clinic).
At each follow-up assessment stage, participants will provide consent via an electronic form before completing the online assessment battery; thus, ongoing consent will be documented at each follow-up time point. The consent procedure will consist of the same process as outlined above - participants will confirm their consent electronically by ticking consent boxes and entering their full name. The investigators will store this information in the consent database.
3.3. Pre/post-intervention Assessments Eligible participants will receive the research equipment by mail and attend a video call appointment (on a secured uOttawa Zoom platform). Participants who are able and willing to come on-site will be invited to do this visit in person at the Sleep Research Unit of the ROMHC rather than over Zoom.
During this first appointment, a research assistant will instruct participants on how to use the study equipment. Participants will also be provided with a brief pre-recorded online video explaining how to use the equipment. The study equipment will include a digital sleep log (containing the core elements of the ''Consensus Sleep Diary'') on the study smartphone app to be filled for 14 days at four time points: baseline (before the intervention starts), post-intervention (after the last treatment week), follow-up 1 (1 month after treatment), and follow-up 2 (6 months after treatment). Participants may fill out the daily sleep log on paper to reduce screen time, if needed. During the last 7 nights of time points 1, 2 and 3, participants will wear. a portable EEG and heart rate headband device (InteraXon, Toronto, Canada). Participants will be informed that they will be able to contact the research assistant at any point throughout the study trial if the participant has any questions and/or concerns.
Participants will complete assessment questionnaires on a secured web-platform (Qualtrics, licensed to the University of Ottawa) at the four time points. These questionnaires should last about 20-30 minutes (see table 1) and will inquire about general demographic and clinical information (including all treatments received for sleep and post-concussion symptoms), sleep, daytime functioning, post-concussion symptoms, mental health, medication use, psychological treatments, and perceptions about the EEG headband. If required, patients can break this up into briefer sessions. The day after the last intervention session, the questionnaire pack will be supplemented by scales assessing treatment adherence and satisfaction (about 5 additional minutes). At the same four time points, participants will be invited to undergo brief cognitive testing on the same online app that will be used for the intervention.
3.4. Collating data from the 360 Concussion Care clinics By consenting to take part to the study, participants will consent for their data, collected as part of the 360 Concussion Care clinics (i.e., our recruitment site) and the TRANSENDENT Concussion Research Program that is taking place through the clinics, to be used in the current study. This consent will be obtained explicitly through the information and consent form. This includes: (1) autonomic measures (e.g. heart rate and blood pressure, tilt test results), (2) aerobic exercise tolerance (Buffalo Concussion Bike Test [BCBT/ Buffalo Concussion Treadmill Test (BCTT]), (3) pupillometry, (4) eye-tracking, (5) salivary fluid (i.e., micro[mi] RNAs) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below), (6) blood (i.e., inflammatory markers) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below, and (7) advanced neuroimaging (MRI), (8) results from questionnaires, diagnoses, and treatment plans (see TRANSCENDENT protocol paper).
3.5. Experimental Conditions Following the pre-intervention assessment, participants will be randomly assigned to one of two arms: an active intervention (CBT-pI) or a control intervention (sleep hygiene), both of which will be delivered on the same digital infrastructure that could be accessed either via a mobile phone or computer (i.e. online app). Their account on this online app will not contain any identifiable information, only an anonymous research participant identification code.
Randomization and blinding:
The randomization process will be done by a computer-generated randomizer, stratified by sex. This will be managed by a research collaborator who will not be directly involved in clinical assessments or data processing. All researchers involved in clinical assessments or data processing will be blinded to the assignment of these different conditions.
Active Intervention:
The digital CBT-pI program is co-developed with lived experts with a history of post-concussion insomnia and is inspired from published recommendations and existing evidence-based CBT-pI programs. It includes four bi-weekly sessions lasting about 30-45 minutes covering all core elements of CBT-I, with some adaptations tailored to better serve people with post-concussion symptoms. For instance, the app design will account for light, sound, and visual field motion sensitivity (e.g. light enlarged text fonts on dark background colours, amber filters, sound processing to lower high pitch tones, minimized scrolling, and slow screen transitions). Participants will be advised to use a large font, reduce the brightness and white point on their screen and/or switch to night settings or add a colour filter to their phone of their choosing. Also, the traditional psychoeducation module will be supplemented with information about sleep changes following concussion (e.g. periods of hypersomnolence, circadian disruptions, and comorbid sleep-related respiratory disturbances often superimposed on insomnia), interactions between sleep and chronic pain, expected course of recovery, the benefits of improving sleep for memory, concentration and mood. As advised by our team members with lived experience, the active intervention arm will also include components of mindfulness-based self-compassion (https://self-compassion.org/) and "Soothe and Calm" Feldenkrais (https://www.feldenkraisaccess.com) videos.
Control Intervention:
The control condition will leverage a digital sleep hygiene program that will mirror the active intervention, as is commonly done in CBT-I trials since sleep hygiene is known to be ineffective to treat insomnia. It will be delivered over the same number/length of bi-weekly sessions using the same digital infrastructure as the CBT-PI program, which will be cloned, but the content will be changed. The content will consist of educational information regarding sleep stages, normal sleep architecture, and healthy sleep practices (e.g., reducing caffeine and alcohol, avoiding exercise and other physical activity just before bed, having a light snack before bed, and keeping the bedroom quiet, and at a comfortable temperature.
Monitoring during treatment:
As per standard procedures during CBT-I, participants will fill out a daily sleep log (containing the core elements of the ''Consensus Sleep Diary'') during the intervention. The Insomnia Severity Index questionnaire will be done at the end of each second week of the intervention, just before participants will do the treatment module. Both the sleep diary and the insomnia severity index questionnaires will be done directly on the digital intervention online app (i.e. on their smartphone or computer). Again, participants will also have the choice to complete these on paper if they prefer. Participants will receive a prompt via the app to remind them of doing the questionnaires and intervention modules.
Adherence will be monitored using sleep schedules documented on the sleep diary and time stamps on the app to track completion of each intervention module. Mid-way through the intervention, participants will be invited for a brief 10-15-minute check-in phone call with a research assistant to ensure the participant does not have any questions or roadblocks with the intervention.
3.6. Additional Post-Assessment Measures Participants will undergo a semi-structured exit interview via a secured Zoom link to gather further insights (about 20-30 minutes). This will aim to gather feedback on participants' experiences throughout the intervention and potential adaptations to better address challenges linked to insomnia treatment in the context of brain-heart function in concussed adults. The exit interview will be recorded (audio only) to enable accurate transcription. Once the transcription is completed, the recordings will be destroyed.
3.7. Deception and debriefing session This study involves a moderate level of deception. To minimize the placebo effect on the control condition, participants will be led to believe that this study will evaluate two different types of sleep interventions. The participant will not be informed that one is the first-line recommended treatment for insomnia (i.e. CBT-I) and the other is anticipated to yield no major benefit for chronic insomnia symptoms.
After participants complete the last follow-up measures, they will be contacted by a research assistant who will explain the deception component of the study and the reason behind it. Participants who were in the control condition will then be offered the active intervention.
- Conditions
- Insomnia, Concussion Post Syndrome
- Being tested
- CBT-pI, Sleep Hygiene
- Keywords
- Cognitive Behavioral Therapy for Insomnia, digital therapy
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Post-Concussion Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBT-pIBehavioural
A digital CBT-pI program co-developed with lived experts with a history of post-concussion insomnia and inspired from published recommendations and existing evidence-based CBT-pI programs.
Sleep HygieneBehavioural
This condition will leverage a digital sleep hygiene program that will mirror the CBT-I intervention
| Study group | Role | What they receive |
|---|---|---|
| Cognitive Behavioural Therapy for Insomnia | Active comparator | Four bi-weekly sessions lasting about 30-45 minutes covering all core elements of CBT-I, with some adaptations tailored to better serve people with post-concussion symptoms. For instance, the app design will account for light, sound, and visual field motion sensitivity (e.g. light enlarged text fonts on dark background colors, amber filters, sound processing to lower high pitch tones, minimized scrolling, and slow screen transitions). Also, the traditional psychoeducation module will be supplemented with information about sleep changes following concussion, interactions between sleep and chronic pain, expected course of recovery, the benefits of improving sleep for memory, concentration and mood. Receives: Behavioral: CBT-pI |
| Placebo | Placebo comparator | A digital sleep hygiene program will mirror the CBT-I intervention. It will be delivered over the same number/length of bi-weekly sessions using the same digital infrastructure as the CBT-PI program. The content will consist of educational information regarding sleep stages, normal sleep architecture, and healthy sleep practices (e.g., reducing caffeine and alcohol, avoiding exercise and other physical activity just before bed, having a light snack before bed, and keeping the bedroom quiet, and at a comfortable temperature). Receives: Behavioral: Sleep Hygiene |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in insomnia symptoms
Changes in insomnia symptoms as indicated by the Insomnia Severity Index-7 (ISI-7) total score from pre-intervention to post-intervention. The ISI-7 is a 7 item questionnaire with total scores ranging from 0 to 28, with higher scores indicating more severe insomnia symptoms.
Measured: From baseline (week 0) to post-intervention (week 10)
Secondary outcomes (28)
Satisfaction with treatment effectiveness as measured with the Modified Treatment Satisfaction Questionnaire for Medication
Satisfaction with treatment effectiveness, side effects, and convenience as rated on the Modified Treatment Satisfaction Questionnaire for Medication (mTSQM). The TSQM is a 14-item self-report scale with total scores ranging from 14-98, higher scores indicating greater treatment satisfaction. This questionnaire has been adapted for the purpose of this study: the term "medication" has been replaced by "intervention", and the term "condition" had been replaced by "symptoms of insomnia or depression".
Measured: 10 weeks
Satisfaction with treatment effectiveness as measured by the Modified Treatment Satisfaction Scale
Perceived perceived symptom improvements as well as overall treatment satisfaction as measured by the Modified Treatment Satisfaction Scale (TSS). The TSS is a 7 item questionnaire with total scores ranging from 7 to 35, with higher scores indicating greater treatment satisfaction. In the present study, the TSS was adapted for insomnia to measure symptom improvement in key areas including insomnia, energy level, work productivity, coping, life enjoyment, hopefulness, self-esteem, and mood.
Measured: 10 weeks
Changes in insomnia symptoms
Changes in insomnia symptoms as indicated by the Insomnia Severity Index-7 (ISI-7) total score from pre-intervention to the first follow-up time point after the end of the intervention. The ISI-7 is a 7 item questionnaire with total scores ranging from 0 to 28, with higher scores indicating more severe insomnia symptoms.
Measured: From baseline (week 0) to the first follow-up (week 14)
Changes in insomnia symptoms
Changes in insomnia symptoms as indicated by the Insomnia Severity Index-7 (ISI-7) total score from pre-intervention to the last follow-up time point after the end of the intervention. The ISI-7 is a 7 item questionnaire with total scores ranging from 0 to 28, with higher scores indicating more severe insomnia symptoms.
Measured: From baseline (week 0) to the last follow-up (week 34)
Treatment acceptability as measured by the Treatment Acceptability/Adherence Scale
Adherence to CBT-I guidelines and perceived helpfulness of treatment guidelines as rated on the Treatment Acceptability/Adherence Scale (TAAS). The TAAS is a 10-item questionnaire with total scores ranging from 10-70, higher scores indicating greater treatment acceptability and adherence.
Measured: 10 weeks
Portable electroencephalogram (EEG) feedback
Assessing the perceptions on using portable electroencephalogram (EEG) using the Questionnaire on Perceptions about Portable EEG using a scale on how the information from the sleep headband aligned with own perceptions from 1 (not at all) to 11 (very much).
Measured: From baseline (week 0) to post-intervention (week 10)
Assess feedback of potential adaptations linked to insomnia treatment
A semi-structured exit interview via a secured Zoom link to gather further insights (about 20-30 minutes). This will aim to gather feedback on participants' experiences throughout the intervention and potential adaptations to better address challenges linked to insomnia treatment in the context of brain-heart function in concussed adults.
Measured: 10 weeks
Changes in EEG-based sleep latency
Changes in EEG-based sleep onset latency from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based latency to REM sleep
Changes in EEG-based latency to REM sleep from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based total sleep time
Changes in EEG-based total sleep time from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based slow wave activity
Changes in the amount of slow wave activity (spectral power in the delta frequency range) from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based slow wave sleep
Changes in the amount of slow wave sleep measured with the EEG headband from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in EEG power spectra
Changes in global EEG power spectrum as measured by the EEG headband from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in the density of sleep slow waves
Changes in the density of sleep slow waves (number of slow wave per minute of NREM sleep) measured by the EEG headband (Muse S Athena) from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Change in the amplitude of sleep slow waves
Change in the amplitude of sleep slow waves (in uV) measured by the EEG headband (Muse S Athena) from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Change in the rate of ascending phase of sleep slow waves
Changes in the rate of ascending phase of sleep slow waves (uV/s) measured by the EEG headband (Muse S Athena) from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Change in the rate of descending phase of sleep slow waves
Changes in the rate of descending phase of sleep slow waves (uV/s) measured by the EEG headband (Muse S Athena) from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in heart rate
Changes in heart rate measures including beats per minutes and heart rate variability from pre- to post-intervention.
Measured: From baseline (week 0) to follow-up (week 14)
Changes in executive function, visual and motor abilities
Assessed by the digital Jewels A task to measure executive function, visual and motor abilities. This task will be measured in seconds (s), a faster time indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in visuospatial and working memory
Assessed by the digital Spatial Span task to measure visuospatial and working memory. This task will be measured in amount of sequences correctly completed, more sequences correctly completed indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in attention and inhibition
Assessed by the digital Pop the Bubbles task to measure attention and inhibition. This task will be measured with the amount of bubbles popped in a certain amount of seconds (s), more bubbles popped within the time frame indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in associative and visual memory
Assessed by the digital Funny Memory task that measures associative and visual memory. This task will be measured in seconds (s), the less time it takes to recall an image indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in executive function, set-shifting, visual and motor abilities
Assessed by the digital Jewels B task that measures executive function, set-shifting, visual and motor abilities. This task will be measured in seconds (s), a faster time indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in attentional control, conflict resolution, and selective attention
Assessed by the digital Flanker task that measures attentional control, conflict resolution, and selective attention. This task will be measured in total trials completed, more trials completed with less errors indicates a better score.
Measured: From baseline (week 0) to the last follow-up (week 34)
Changes in subjective pre-sleep arousal
Changes in subjective pre-sleep arousal as rated on the Pre-Sleep Arousal Scale (PSAS) from pre- to post-intervention. The PSAS is a 16-item questionnaire with total scores ranging from 16 to 80, with higher scores indicating greater cognitive and somatic pre-sleep arousal.
Measured: From baseline (week 0) to post-intervention (week 10)
Changes in subjective dysautonomia
Assessed using the Composite Autonomic Symptom Score 31 (Compass-31) questionnaire that includes 31 questions that assesses the severity and frequency of autonomic symtoms in the past year.
Measured: From baseline (week 0) to last follow-up (week 34)
Changes in anxiety symptoms
Assessed using the General Anxiety Disorder-7 (GAD-7) questionnaire which evaluates the severity off anxiety symptoms. This 7 item questionnaire assesses the severity of anxiety symptoms over the past 2 weeks from "not at all" to "nearly every day".
Measured: From baseline (week 0) to follow-up (week 34)
Changes in beliefs about sleep
Assessed by the Dysfunctional Beliefs About Sleep (DBAS-16) questionnaire. This 16 item questionnaire assesses beliefs about sleep from 0 (strongly disagree) to 10 (strongly agree).
Measured: From baseline (week 0) to post-intervention (week 10)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study startJun 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (50)Papers the sponsor has linked to this study.
- Other trials for InsomniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Ottawa
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rébecca Robillard, University of Ottawa
- Investigators
- Rebecca Robillard, Principal investigator, University of Ottawa Institute of Mental Health Research at The Royal
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07636408
- Sponsor's protocol ID
- 373
- Acronym
- CBT-pI
- Status last verified
- Jun 2026
- First submitted
- 5 May 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Sharing of data outside of the primary institution leading the study such as through collaboration will be arranged only after express agreement with the PI.
Publications
Zhang B, Wing YK. Sex differences in insomnia: a meta-analysis. Sleep. 2006 Jan;29(1):85-93. doi: 10.1093/sleep/29.1.85.
PubMed 16453985Zhang G, Wang S, Ma P, Pan J. Neurophysiology and Molecular Basis of Cognitive Behavioral Therapy for Patients with Insomnia: Implications for Non-Pharmacological Approaches. J Integr Neurosci. 2024 Oct 31;23(11):200. doi: 10.31083/j.jin2311200.
PubMed 39613462Zhang P, Tan CW, Chen GH, Ge YJ, Xu J, Xia L, Wang F, Li XY, Kong XY. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist? Sleep Med. 2018 Aug;48:163-171. doi: 10.1016/j.sleep.2017.12.012. Epub 2018 Feb 13.
PubMed 29957487Zemek R, Albrecht LM, Johnston S, Leddy J, Ledoux AA, Reed N, Silverberg N, Yeates K, Lamoureux M, Anderson C, Barrowman N, Beauchamp MH, Chen K, Chintoh A, Cortel-LeBlanc A, Cortel-LeBlanc M, Corwin DJ, Cowle S, Dalton K, Dawson J, Dodd A, El Emam K, Emery C, Fox E, Fuselli P, Gagnon IJ, Giza C, Hicks S, Howell DR, Kutcher SA, Lalonde C, Mannix RC, Master CL, Mayer AR, Osmond MH, Robillard R, Schneider KJ, Tanuseputro P, Terekhov I, Webster R, Wellington CL; TRANSCENDENT Concussion Integrated Discovery Program. TRANSCENDENT (Transforming Research by Assessing Neuroinformatics across the Spectrum of Concussion by Embedding iNterdisciplinary Data-collection to Enable Novel Treatments): protocol for a prospective observational cohort study of concussion patients with embedded comparative effectiveness research within a network of learning health system concussion clinics in Canada. BMJ Open. 2025 Apr 22;15(4):e095292. doi: 10.1136/bmjopen-2024-095292.
PubMed 40262965Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem. 2010 Nov;56(11):1733-41. doi: 10.1373/clinchem.2010.147405. Epub 2010 Sep 16.
PubMed 20847327Tomfohr-Madsen L, Madsen JW, Bonneville D, Virani S, Plourde V, Barlow KM, Yeates KO, Brooks BL. A Pilot Randomized Controlled Trial of Cognitive-Behavioral Therapy for Insomnia in Adolescents With Persistent Postconcussion Symptoms. J Head Trauma Rehabil. 2020 Mar/Apr;35(2):E103-E112. doi: 10.1097/HTR.0000000000000504.
PubMed 31246882Tabor JB, Penner LC, Galarneau JM, Josafatow N, Cooper J, Ghodsi M, Huang J, Fraser DD, Smirl J, Esser MJ, Yeates KO, Wellington CL, Debert CT, Emery CA. Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion. JAMA Netw Open. 2024 Sep 3;7(9):e2431959. doi: 10.1001/jamanetworkopen.2024.31959.
PubMed 39235809Tabor JB, Penner LC, Cooper JG, Ghodsi M, Galarneau JM, Fraser DD, Emery CA, Wellington CL, Debert CT. Characterizing Factors Influencing Baseline Plasma Biomarkers for Sport-Related Concussion in Adolescents. J Neurotrauma. 2023 Aug;40(15-16):1638-1650. doi: 10.1089/neu.2022.0501. Epub 2023 Apr 6.
PubMed 36852497Tabor JB, Galarneau JM, Penner LC, Cooper J, Ghodsi M, Fraser DD, Wellington CL, Debert CT, Emery CA. Use of Biostatistical Models to Manage Replicate Error in Concussion Biomarker Research. JAMA Netw Open. 2023 Oct 2;6(10):e2339733. doi: 10.1001/jamanetworkopen.2023.39733.
PubMed 37870831Spencer, R. J., Collings, A. S., & Bloor, L. E. (2019). Cognitive behavioral therapy for insomnia as treatment for post-concussive symptoms. Medical Research, 1(1), 1-7. https://doi.org/10.35702/mrj.10005
Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017 Jan 26;17(1):88. doi: 10.1186/s12913-017-2031-8.
PubMed 28126032Savin KL, Clark TL, Perez-Ramirez P, Allen TS, Tristao Parra M, Gallo LC. The Effect of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Cardiometabolic Health Biomarkers: A Systematic Review of Randomized Controlled Trials. Behav Sleep Med. 2023 Nov 2;21(6):671-694. doi: 10.1080/15402002.2022.2154213. Epub 2022 Dec 7.
PubMed 36476211Rowe RK. Deep sleep helps the heart to heal. Nature. 2024 Nov;635(8037):45-46. doi: 10.1038/d41586-024-03394-2. No abstract available.
PubMed 39478066Rogelj B, Giese KP. Expression and function of brain specific small RNAs. Rev Neurosci. 2004;15(3):185-98. doi: 10.1515/revneuro.2004.15.3.185.
PubMed 15357141Prados G, Miro E, Martinez MP, Sanchez AI, Pichot V, Medina-Casado M, Chouchou F. Effect of Cognitive-Behavioral Therapy on Nocturnal Autonomic Activity in Patients with Fibromyalgia: A Preliminary Study. Brain Sci. 2022 Jul 20;12(7):947. doi: 10.3390/brainsci12070947.
PubMed 35884753
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhancing Sleep to Improve Brain-heart Functions in People With Persistent Post-concussion Symptoms
- ClinicalTrials.gov ID
- NCT07636408
- Acronym / sponsor ID
- CBT-pI / 373
- Conditions
- Insomnia, Concussion Post Syndrome
- Keywords
- Cognitive Behavioral Therapy for Insomnia, digital therapy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University of OttawaUniversity, hospital or other
- Study start
- Jun 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 9 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project is designed as a randomized controlled trial (RCT), with an active control group. Sleep and heart rate will be monitored at home for 1 week before and after the intervention. Questionnaires will be completed from home before, during and 8 weeks after the end of the Intervention. The Cognitive Behavioural Therapy for Insomnia, adapted for post-concussed individuals (CBT-pI) and control interventions, will be delivered on a digital online platform over an 8-week period. Participants in the control arm will be offered CBT-pI after the follow-up period. All intervention arms will be delivered as adjuncts to standard clinical care. All other treatments received during the intervention will be documented.
Detailed description
- Background and Rationale Up to 50% of individuals who sustain a concussion experience sleep disturbances. Poor sleep has been found predictive of poorer outcomes in post-concussion recovery. In Canada, insomnia constitutes a major burden upon public health. Insomnia not only impairs sleep quality but also exacerbates cognitive, emotional, and physiological post-concussion symptoms, including cardiovascular dysfunctions, such as elevated heart rate and sympathetic overactivation; thus, possibly leading to delayed recovery following a concussion. Furthermore, recent work in chronic insomnia identified increased levels of brain microstructure injury biomarkers previously linked to concussion. These disruptions can potentially interfere with brain-heart functions and delay post-concussion recovery. As such, treating insomnia may result in better post-concussion recovery, which may notably be observable through biomarkers linked to brain-heart health. Cognitive-Behavioural Therapy treatment for insomnia (CBT-I) is the first line of treatment recommended for chronic primary insomnia sufferers. It combines multipronged strategies involving education and progressive personalized sleep manipulations to address the maladaptive cognitive and behavioural processes contributing to the maintenance of insomnia. Five distinct intervention components - stimulus control, time in bed restriction therapy, psychoeducation about sleep, cognitive therapy, and relaxation training - are included within the CBT-I framework. CBT-I has been found effective to address sleep issues emerging after a concussion, with documented benefits for post-concussion recovery. This may notably operate via the restoration of brain-heart functions since CBT-I enhances brain functions following concussions, may influence autonomic regulation by reducing hyperarousal and sympathetic overactivation, and improves cardiovascular outcomes. One of the putative mechanisms of action of CBT-I resides in increased deep sleep due to enhanced sleep pressure. Deep sleep is a state characterized by high amplitude low frequency brain activity in the delta frequency range on the electroencephalogram (EEG). Recent discoveries highlight the role of deep sleep in autonomic regulation and healing processes. Post-concussion sleep has been associated with increased deep sleep. One may postulate that higher increases in delta activity driven by CBT-I may be associated with enhanced autonomic functions and post-concussion symptoms recovery. The investigators recently expanded previous results suggesting that individuals with insomnia have low coherence between brain and heart activity. To the best of our knowledge, research has yet to investigate whether successful insomnia treatment, through CBT-I, restores brain-heart interactions, and how changes in brain, heart, and brain-heart interactions may relate to post-concussion symptoms recovery following CBT-I.
- Study Objectives Primary objective:
- Evaluate the efficacy of a digital CBT-I program adapted for post-concussion syndrome (CBT-pI) on insomnia symptoms (primary outcome) and biomarkers related to post-concussion brain-heart function (secondary outcomes) Secondary objectives:
- Evaluate treatment acceptability and satisfaction
- Collate feedback about potential adaptations to better address challenges linked to insomnia treatment in the context of post-concussion brain-heart function
- Explore putative brain-heart mechanisms associated with CBT-pI responses based on EEG markers, heart rate and heart rate variability, sleep-based EEG-ECG interactions, and cognitive performance
- Methods
3.1. Contact Pathway Participants will be recruited through the 360 Concussion Care (360CC) clinic. The participants will be referred by clinicians at this clinic to members of the research team. Clinicians will identify patients they would like to refer to the study, request that these patients fill out the "Permission to be contacted form", and send this form to the research team. A research assistant will then contact the potential participant through email to send them a summary of the study and a link to complete an anonymous online screening form for the first set of eligibility criteria on a secured web platform (Qualtrics, www.qualtrics.com; license held via the University of Ottawa) and a unique identification code. The first question of this online form will ask participants to confirm their consent to take part in the screening process. This will be documented in the screening database. The second question of this online screening form will ask participants to insert their unique anonymous research screening code. This screening form will notably include items assessing neurologic and psychiatric history and medications, and will include the Sleep Condition Indicator (SCI), WHO-ASSIST item 2, Sleep Disorders Symptoms Checklist-25 (SDS-CL-25), and Epworth Sleepiness Scale. It should take between 10 and 15 minutes to complete.
3.2. Ongoing Consent Procedure For participants found to be eligible after the screening, the research assistant will call participants to summarize the next steps of the study verbally and address any questions or concerns that participants may have. At which point, verbal consent will be obtained to conduct a structured interview using the Mini International Neuropsychiatric Interview (M.I.N.I) and the insomnia module of the SCID to determine the last set of eligibility criteria.
After this interview, eligible participants will be sent an electronic form containing the information and consent form (ICF) and will have as much time as the participant needs to read it at home before enrolling in the study. As part of that same electronic form, the participant will confirm consent by ticking consent boxes and entering their full name. This information will be stored in a consent database showing the participant's full name and consent date, which will be kept on restricted-access folders on the ROMHC's server in separate files than the research data. This online consent form was created based on published guidelines from peer-reviewed articles. Special care will be given to ensure that participants understand that their participation is entirely voluntary and that the participant can withdraw from the study at any stage (without any consequence on the treatment[s] they receive at the 360CC clinic or their relationship with any of the clinicians at the 360CC clinic).
At each follow-up assessment stage, participants will provide consent via an electronic form before completing the online assessment battery; thus, ongoing consent will be documented at each follow-up time point. The consent procedure will consist of the same process as outlined above - participants will confirm their consent electronically by ticking consent boxes and entering their full name. The investigators will store this information in the consent database.
3.3. Pre/post-intervention Assessments Eligible participants will receive the research equipment by mail and attend a video call appointment (on a secured uOttawa Zoom platform). Participants who are able and willing to come on-site will be invited to do this visit in person at the Sleep Research Unit of the ROMHC rather than over Zoom.
During this first appointment, a research assistant will instruct participants on how to use the study equipment. Participants will also be provided with a brief pre-recorded online video explaining how to use the equipment. The study equipment will include a digital sleep log (containing the core elements of the ''Consensus Sleep Diary'') on the study smartphone app to be filled for 14 days at four time points: baseline (before the intervention starts), post-intervention (after the last treatment week), follow-up 1 (1 month after treatment), and follow-up 2 (6 months after treatment). Participants may fill out the daily sleep log on paper to reduce screen time, if needed. During the last 7 nights of time points 1, 2 and 3, participants will wear. a portable EEG and heart rate headband device (InteraXon, Toronto, Canada). Participants will be informed that they will be able to contact the research assistant at any point throughout the study trial if the participant has any questions and/or concerns.
Participants will complete assessment questionnaires on a secured web-platform (Qualtrics, licensed to the University of Ottawa) at the four time points. These questionnaires should last about 20-30 minutes (see table 1) and will inquire about general demographic and clinical information (including all treatments received for sleep and post-concussion symptoms), sleep, daytime functioning, post-concussion symptoms, mental health, medication use, psychological treatments, and perceptions about the EEG headband. If required, patients can break this up into briefer sessions. The day after the last intervention session, the questionnaire pack will be supplemented by scales assessing treatment adherence and satisfaction (about 5 additional minutes). At the same four time points, participants will be invited to undergo brief cognitive testing on the same online app that will be used for the intervention.
3.4. Collating data from the 360 Concussion Care clinics By consenting to take part to the study, participants will consent for their data, collected as part of the 360 Concussion Care clinics (i.e., our recruitment site) and the TRANSENDENT Concussion Research Program that is taking place through the clinics, to be used in the current study. This consent will be obtained explicitly through the information and consent form. This includes: (1) autonomic measures (e.g. heart rate and blood pressure, tilt test results), (2) aerobic exercise tolerance (Buffalo Concussion Bike Test [BCBT/ Buffalo Concussion Treadmill Test (BCTT]), (3) pupillometry, (4) eye-tracking, (5) salivary fluid (i.e., micro[mi] RNAs) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below), (6) blood (i.e., inflammatory markers) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below, and (7) advanced neuroimaging (MRI), (8) results from questionnaires, diagnoses, and treatment plans (see TRANSCENDENT protocol paper).
3.5. Experimental Conditions Following the pre-intervention assessment, participants will be randomly assigned to one of two arms: an active intervention (CBT-pI) or a control intervention (sleep hygiene), both of which will be delivered on the same digital infrastructure that could be accessed either via a mobile phone or computer (i.e. online app). Their account on this online app will not contain any identifiable information, only an anonymous research participant identification code.
Randomization and blinding:
The randomization process will be done by a computer-generated randomizer, stratified by sex. This will be managed by a research collaborator who will not be directly involved in clinical assessments or data processing. All researchers involved in clinical assessments or data processing will be blinded to the assignment of these different conditions.
Active Intervention:
The digital CBT-pI program is co-developed with lived experts with a history of post-concussion insomnia and is inspired from published recommendations and existing evidence-based CBT-pI programs. It includes four bi-weekly sessions lasting about 30-45 minutes covering all core elements of CBT-I, with some adaptations tailored to better serve people with post-concussion symptoms. For instance, the app design will account for light, sound, and visual field motion sensitivity (e.g. light enlarged text fonts on dark background colours, amber filters, sound processing to lower high pitch tones, minimized scrolling, and slow screen transitions). Participants will be advised to use a large font, reduce the brightness and white point on their screen and/or switch to night settings or add a colour filter to their phone of their choosing. Also, the traditional psychoeducation module will be supplemented with information about sleep changes following concussion (e.g. periods of hypersomnolence, circadian disruptions, and comorbid sleep-related respiratory disturbances often superimposed on insomnia), interactions between sleep and chronic pain, expected course of recovery, the benefits of improving sleep for memory, concentration and mood. As advised by our team members with lived experience, the active intervention arm will also include components of mindfulness-based self-compassion (https://self-compassion.org/) and "Soothe and Calm" Feldenkrais (https://www.feldenkraisaccess.com) videos.
Control Intervention:
The control condition will leverage a digital sleep hygiene program that will mirror the active intervention, as is commonly done in CBT-I trials since sleep hygiene is known to be ineffective to treat insomnia. It will be delivered over the same number/length of bi-weekly sessions using the same digital infrastructure as the CBT-PI program, which will be cloned, but the content will be changed. The content will consist of educational information regarding sleep stages, normal sleep architecture, and healthy sleep practices (e.g., reducing caffeine and alcohol, avoiding exercise and other physical activity just before bed, having a light snack before bed, and keeping the bedroom quiet, and at a comfortable temperature.
Monitoring during treatment:
As per standard procedures during CBT-I, participants will fill out a daily sleep log (containing the core elements of the ''Consensus Sleep Diary'') during the intervention. The Insomnia Severity Index questionnaire will be done at the end of each second week of the intervention, just before participants will do the treatment module. Both the sleep diary and the insomnia severity index questionnaires will be done directly on the digital intervention online app (i.e. on their smartphone or computer). Again, participants will also have the choice to complete these on paper if they prefer. Participants will receive a prompt via the app to remind them of doing the questionnaires and intervention modules.
Adherence will be monitored using sleep schedules documented on the sleep diary and time stamps on the app to track completion of each intervention module. Mid-way through the intervention, participants will be invited for a brief 10-15-minute check-in phone call with a research assistant to ensure the participant does not have any questions or roadblocks with the intervention.
3.6. Additional Post-Assessment Measures Participants will undergo a semi-structured exit interview via a secured Zoom link to gather further insights (about 20-30 minutes). This will aim to gather feedback on participants' experiences throughout the intervention and potential adaptations to better address challenges linked to insomnia treatment in the context of brain-heart function in concussed adults. The exit interview will be recorded (audio only) to enable accurate transcription. Once the transcription is completed, the recordings will be destroyed.
3.7. Deception and debriefing session This study involves a moderate level of deception. To minimize the placebo effect on the control condition, participants will be led to believe that this study will evaluate two different types of sleep interventions. The participant will not be informed that one is the first-line recommended treatment for insomnia (i.e. CBT-I) and the other is anticipated to yield no major benefit for chronic insomnia symptoms.
After participants complete the last follow-up measures, they will be contacted by a research assistant who will explain the deception component of the study and the reason behind it. Participants who were in the control condition will then be offered the active intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cognitive Behavioural Therapy for Insomnia | Active comparator | Behavioral: CBT-pIFour bi-weekly sessions lasting about 30-45 minutes covering all core elements of CBT-I, with some adaptations tailored to better serve people with post-concussion symptoms. For instance, the app design will account for light, sound, and visual field motion sensitivity (e.g. light enlarged text fonts on dark background colors, amber filters, sound processing to lower high pitch tones, minimized scrolling, and slow screen transitions). Also, the traditional psychoeducation module will be supplemented with information about sleep changes following concussion, interactions between sleep and chronic pain, expected course of recovery, the benefits of improving sleep for memory, concentration and mood. |
| Placebo | Placebo comparator | Behavioral: Sleep HygieneA digital sleep hygiene program will mirror the CBT-I intervention. It will be delivered over the same number/length of bi-weekly sessions using the same digital infrastructure as the CBT-PI program. The content will consist of educational information regarding sleep stages, normal sleep architecture, and healthy sleep practices (e.g., reducing caffeine and alcohol, avoiding exercise and other physical activity just before bed, having a light snack before bed, and keeping the bedroom quiet, and at a comfortable temperature). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults 18 years and older
- Experiencing persisting post-concussion symptoms > 4 weeks but no more than 12 months post-injury as measured based on home-made screening questions and the Sport Concussion Assessment Tool (SCAT6)
- Having a Sleep Condition Indicator score suggestive of insomnia (SCI =/< 15, adapted to enable the inclusion of insomnia symptoms over at least 1 month)
- Meeting diagnostic criteria for insomnia disorder on the SCID
- Having a smartphone, tablet or computer and willingness to install a sleep intervention application on it
Key exclusion criteria (10 listed)
- Having undergone another CBT-I program within the past 6 months
- Current diagnosis of bipolar disorder, psychotic disorder, or substance use disorder confirmed by the M.I.N.I.
- Self-reported substance use disorder (i.e., alcohol, cannabis, or illicit drugs) or =/> monthly use of illicit drugs reported on item-2 of the WHO-ASSIST (except tobacco, alcohol, and cannabis)
- Body mass index > 45
- Shift work or rotating shifts within 1 month of study entry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBT-pIA digital CBT-pI program co-developed with lived experts with a history of post-concussion insomnia and inspired from published recommendations and existing evidence-based CBT-pI programs. | Behavioural | Cognitive Behavioural Therapy for Insomnia |
| Sleep HygieneThis condition will leverage a digital sleep hygiene program that will mirror the CBT-I intervention | Behavioural | Placebo |
Primary outcome
Changes in insomnia symptoms
Time frame: From baseline (week 0) to post-intervention (week 10)
Changes in insomnia symptoms as indicated by the Insomnia Severity Index-7 (ISI-7) total score from pre-intervention to post-intervention. The ISI-7 is a 7 item questionnaire with total scores ranging from 0 to 28, with higher scores indicating more severe insomnia symptoms.
28 secondary outcomes
Satisfaction with treatment effectiveness as measured with the Modified Treatment Satisfaction Questionnaire for Medication
Time frame: 10 weeks
Satisfaction with treatment effectiveness as measured by the Modified Treatment Satisfaction Scale
Time frame: 10 weeks
Changes in insomnia symptoms
Time frame: From baseline (week 0) to the first follow-up (week 14)
Changes in insomnia symptoms
Time frame: From baseline (week 0) to the last follow-up (week 34)
Treatment acceptability as measured by the Treatment Acceptability/Adherence Scale
Time frame: 10 weeks
Portable electroencephalogram (EEG) feedback
Time frame: From baseline (week 0) to post-intervention (week 10)
Assess feedback of potential adaptations linked to insomnia treatment
Time frame: 10 weeks
Changes in EEG-based sleep latency
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based latency to REM sleep
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based total sleep time
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based slow wave activity
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in EEG-based slow wave sleep
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in EEG power spectra
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in the density of sleep slow waves
Time frame: From baseline (week 0) to follow-up (week 14)
Change in the amplitude of sleep slow waves
Time frame: From baseline (week 0) to follow-up (week 14)
Change in the rate of ascending phase of sleep slow waves
Time frame: From baseline (week 0) to follow-up (week 14)
Change in the rate of descending phase of sleep slow waves
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in heart rate
Time frame: From baseline (week 0) to follow-up (week 14)
Changes in executive function, visual and motor abilities
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in visuospatial and working memory
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in attention and inhibition
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in associative and visual memory
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in executive function, set-shifting, visual and motor abilities
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in attentional control, conflict resolution, and selective attention
Time frame: From baseline (week 0) to the last follow-up (week 34)
Changes in subjective pre-sleep arousal
Time frame: From baseline (week 0) to post-intervention (week 10)
Changes in subjective dysautonomia
Time frame: From baseline (week 0) to last follow-up (week 34)
Changes in anxiety symptoms
Time frame: From baseline (week 0) to follow-up (week 34)
Changes in beliefs about sleep
Time frame: From baseline (week 0) to post-intervention (week 10)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Background: PubMed 16453985Zhang B, Wing YK. Sex differences in insomnia: a meta-analysis. Sleep. 2006 Jan;29(1):85-93. doi: 10.1093/sleep/29.1.85.
- Background: PubMed 39613462Zhang G, Wang S, Ma P, Pan J. Neurophysiology and Molecular Basis of Cognitive Behavioral Therapy for Patients with Insomnia: Implications for Non-Pharmacological Approaches. J Integr Neurosci. 2024 Oct 31;23(11):200. doi: 10.31083/j.jin2311200.
- Background: PubMed 29957487Zhang P, Tan CW, Chen GH, Ge YJ, Xu J, Xia L, Wang F, Li XY, Kong XY. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist? Sleep Med. 2018 Aug;48:163-171. doi: 10.1016/j.sleep.2017.12.012. Epub 2018 Feb 13.
- Background: PubMed 40262965Zemek R, Albrecht LM, Johnston S, Leddy J, Ledoux AA, Reed N, Silverberg N, Yeates K, Lamoureux M, Anderson C, Barrowman N, Beauchamp MH, Chen K, Chintoh A, Cortel-LeBlanc A, Cortel-LeBlanc M, Corwin DJ, Cowle S, Dalton K, Dawson J, Dodd A, El Emam K, Emery C, Fox E, Fuselli P, Gagnon IJ, Giza C, Hicks S, Howell DR, Kutcher SA, Lalonde C, Mannix RC, Master CL, Mayer AR, Osmond MH, Robillard R, Schneider KJ, Tanuseputro P, Terekhov I, Webster R, Wellington CL; TRANSCENDENT Concussion Integrated Discovery Program. TRANSCENDENT (Transforming Research by Assessing Neuroinformatics across the Spectrum of Concussion by Embedding iNterdisciplinary Data-collection to Enable Novel Treatments): protocol for a prospective observational cohort study of concussion patients with embedded comparative effectiveness research within a network of learning health system concussion clinics in Canada. BMJ Open. 2025 Apr 22;15(4):e095292. doi: 10.1136/bmjopen-2024-095292.
- Background: PubMed 20847327Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem. 2010 Nov;56(11):1733-41. doi: 10.1373/clinchem.2010.147405. Epub 2010 Sep 16.
- Background: PubMed 31246882Tomfohr-Madsen L, Madsen JW, Bonneville D, Virani S, Plourde V, Barlow KM, Yeates KO, Brooks BL. A Pilot Randomized Controlled Trial of Cognitive-Behavioral Therapy for Insomnia in Adolescents With Persistent Postconcussion Symptoms. J Head Trauma Rehabil. 2020 Mar/Apr;35(2):E103-E112. doi: 10.1097/HTR.0000000000000504.
- Background: PubMed 39235809Tabor JB, Penner LC, Galarneau JM, Josafatow N, Cooper J, Ghodsi M, Huang J, Fraser DD, Smirl J, Esser MJ, Yeates KO, Wellington CL, Debert CT, Emery CA. Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion. JAMA Netw Open. 2024 Sep 3;7(9):e2431959. doi: 10.1001/jamanetworkopen.2024.31959.
- Background: PubMed 36852497Tabor JB, Penner LC, Cooper JG, Ghodsi M, Galarneau JM, Fraser DD, Emery CA, Wellington CL, Debert CT. Characterizing Factors Influencing Baseline Plasma Biomarkers for Sport-Related Concussion in Adolescents. J Neurotrauma. 2023 Aug;40(15-16):1638-1650. doi: 10.1089/neu.2022.0501. Epub 2023 Apr 6.
- Background: PubMed 37870831Tabor JB, Galarneau JM, Penner LC, Cooper J, Ghodsi M, Fraser DD, Wellington CL, Debert CT, Emery CA. Use of Biostatistical Models to Manage Replicate Error in Concussion Biomarker Research. JAMA Netw Open. 2023 Oct 2;6(10):e2339733. doi: 10.1001/jamanetworkopen.2023.39733.
- BackgroundSpencer, R. J., Collings, A. S., & Bloor, L. E. (2019). Cognitive behavioral therapy for insomnia as treatment for post-concussive symptoms. Medical Research, 1(1), 1-7. https://doi.org/10.35702/mrj.10005
- Background: PubMed 28126032Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017 Jan 26;17(1):88. doi: 10.1186/s12913-017-2031-8.
- Background: PubMed 36476211Savin KL, Clark TL, Perez-Ramirez P, Allen TS, Tristao Parra M, Gallo LC. The Effect of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Cardiometabolic Health Biomarkers: A Systematic Review of Randomized Controlled Trials. Behav Sleep Med. 2023 Nov 2;21(6):671-694. doi: 10.1080/15402002.2022.2154213. Epub 2022 Dec 7.
- Individual participant dataSharing planned: Yes. Sharing of data outside of the primary institution leading the study such as through collaboration will be arranged only after express agreement with the PI.
Related trials for Insomnia
Active, not recruiting
Innovating CBT-I for Cancer Survivors: An Optimization Trial
Cancer Survivorship, Insomnia
Not yet recruiting
AI-Driven Digital Therapeutic for Insomnia: Development and Clinical Validation
Insomnia
Not yet recruiting
Acceptance and Commitment Therapy Plus Physiotherapy for Chronic Low Back Pain
Low Back Pain
Not yet recruiting
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Insomnia During the Withdrawal-Rehabilitation Period of Methamphetamine Use Disorder
Insomnia
Active, not recruitingObservational study
Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients
Chronic Insomnia, Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rebecca Robillard principal investigator
University of Ottawa Institute of Mental Health Research at The Royal
Questions about this trial
What is this clinical trial studying?
A study testing CBT-pI and Sleep Hygiene in people with Insomnia and Concussion Post Syndrome, run by University of Ottawa.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rebecca Robillard (613-722-6521 ext. 6279, Rebecca.Robillard@uottawa.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in insomnia symptoms (time frame: From baseline (week 0) to post-intervention (week 10)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07636408, which also lists 50 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.